An interventional study of Oxytocin and Carbetocin in Postpartum Hemorrhage (Primary), sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital. Recruiting at 1 site in Canada. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing oxytocin in Postpartum Hemorrhage — 8 open to participants now, 9 under way, 1 of them phase 3. Oxytocin · Postpartum Hemorrhage.
Among the 64 studies testing oxytocin in Postpartum Hemorrhage, this one is the 45th largest by planned enrollment, is one of 3 that started in 2025, is one of 37 with no phase, and was the 60th registered.
471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.
Browse Postpartum Hemorrhage studies →8 of the 64 studies testing oxytocin in Postpartum Hemorrhage are open now, in 4 countries. Recruiting first, the newest first:
Mansoura University · Sites in Saudi Arabia
Ages 18–45 · Women only
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Sites in Canada
Ages 18–50 · Women only · Healthy volunteers
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Sites in Canada
Ages 18–50 · Women only · Healthy volunteers
Khyber Girls Medical College · Sites in Pakistan
Ages 18–40 · Women only
Assiut University
Ages 18–45 · Women only
By country, each count listing its studies:
Oxytocin: first FDA approval 1980 (SYNTOCINON). What it is approved for, and how studies give it, is on its page →
Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 40 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 8 · Phase 4 9
First in 2002; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 148 across 362 interventional studies indexed under Postpartum Hemorrhage.
Median enrollment 108 across the 64 interventional studies. Of the 42 that completed or were terminated, 4 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 64 have an industry lead sponsor. The 10 most frequent:
Samuel Lunenfeld Research Institute, Mount Sinai Hospital is the lead sponsor of 138 studies on the registry; 17 are open to participants now.
34 studies in Postpartum Hemorrhage by Samuel Lunenfeld Research Institute, Mount Sinai Hospital: 5 open now, 6 under way, none of them phase 3. Of 28 finished, 0 (0%) have results posted.
Among the 34 studies in Postpartum Hemorrhage by Samuel Lunenfeld Research Institute, Mount Sinai Hospital, this one is the 16th largest by planned enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2025, is one of 32 with no phase, and was the 32nd registered.
Samuel Lunenfeld Research Institute, Mount Sinai Hospital’s Postpartum Hemorrhage studies by the year they started, since 2007.
4 of the studies testing oxytocin in Postpartum Hemorrhage that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05290129Samuel Lunenfeld Research Institute, Mount Sinai HospitalOxytocin Maintenance Infusion in Labouring Women Undergoing Cesarean Delivery: an Up-down Sequential Allocation Study | 2026-12 |
| NCT06333340Samuel Lunenfeld Research Institute, Mount Sinai HospitalComparative Efficacy of Carbetocin and Oxytocin in Parturients at Risk of Atonic Postpartum Hemorrhage Undergoing Elective Cesarean Delivery | 2026-12 |
| NCT07784478Khyber Girls Medical CollegeEffect of Oxytocin Bolus Versus Slow Infusion on Haemodynamic Stability During Caesarean Section Under Spinal Anaesthesia | 2027-04-01 |
| NCT06930391Samuel Lunenfeld Research Institute, Mount Sinai HospitalEffect of Extracellular Calcium on Carbetocin Mediated Contractility in Human Myometrium | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 64 studies testing oxytocin in Postpartum Hemorrhage, from their registry updates:
Among Samuel Lunenfeld Research Institute, Mount Sinai Hospital’s 34 in Postpartum Hemorrhage:
This tab as a report to print or save as PDF → With an account.
Postpartum hemorrhage (PPH) continues to be an increasing problem globally. Uterotonics play an essential role in the pharmacological management of uterine atony. Carbetocin, a long acting analog of oxytocin has been recommended as a first line uterotonic for PPH prophylaxis at cesarean delivery. Considering many woman have associated comorbidities and are at high risk of PPH, finding alternative pharmacological agents is essential. Calcium is a key factor for myometrial contractions and calcium blood levels can be low at the end of pregnancy. Both hypocalcemia and hypercalcemia could lead to a decrease in myometrial contractions. It is already been demonstrated that in both desensitized and naïve myometrium, normocalcemia provides a better uterine tone compared to hypo and hypercalcemia when oxytocin is given as the first uterotonic drug.
Currently, the role of extracelullar calcium in carbetocin- induced contractility is unknown. This will be the first ex vivo study to test the effects of extracellular calcium on oxytocin pretreated and naive myometrium. The results of this study will provide evidence on the use of this safe drug in clinical practice, particularly in women with labour arrest, and provide alternative pharmacological strategies to both prevention and treatment of PPH, thus improving our clinical practice.
The investigators hypothesize that extracellular normocalcemia would provide superior carbetocin-mediated contractility in both naive and oxytocin-pretreated myometrium compared with hypercalcemia and hypocalcemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Dose-response testing with 1.25nM calcium chloride, and increasing concentrations of carbetocin in a pattern of 1 log molar increase every 10 min, from 10-10 M to 10-5 M, with NO oxytocin pre-exposure
Drug: Carbetocin · Drug: Calcium
Dose-response testing with 2.5nM calcium chloride, and increasing concentrations of carbetocin in a pattern of 1 log molar increase every 10 min, from 10-10 M to 10-5 M, with NO oxytocin pre-exposure
Drug: Carbetocin · Drug: Calcium
Dose-response testing with 5.0nM calcium chloride, and increasing concentrations of carbetocin in a pattern of 1 log molar increase every 10 min, from 10-10 M to 10-5 M, with NO oxytocin pre-exposure
Drug: Carbetocin · Drug: Calcium
Dose-response testing with 1.25nM calcium chloride, and increasing concentrations of carbetocin in a pattern of 1 log molar increase every 10 min, from 10-10 M to 10-5 M, with oxytocin pre-exposure
Drug: Oxytocin · Drug: Carbetocin · Drug: Calcium
Dose-response testing with 2.5nM calcium chloride, and increasing concentrations of carbetocin in a pattern of 1 log molar increase every 10 min, from 10-10 M to 10-5 M, with oxytocin pre-exposure
Drug: Oxytocin · Drug: Carbetocin · Drug: Calcium
Dose-response testing with 5.0nM calcium chloride, and increasing concentrations of carbetocin in a pattern of 1 log molar increase every 10 min, from 10-10 M to 10-5 M, with oxytocin pre-exposure
Drug: Oxytocin · Drug: Carbetocin · Drug: Calcium
Oxytocin 10-5M will be added to 3 groups of myometrial strips for 2 hours to induce desensitization.
Increasing concentrations of carbetocin in a pattern of 1 log molar increase every 10 min, from 10-10 M to 10-5 M
Calcium chloride in the following concentrations:1.25mM, 2.5mM and 5.0mM.
Motility index
Motility index (MI) is a calculated outcome, based on the formula: frequency/(10 x amplitude). Frequency and amplitude are secondary outcome measures as described below. The analysis is undertaken by attaching myometrial strips between an isometric force transducer and the base of an organ bath chamber.
Time frame: 4 hours
Amplitude of contraction
The maximum extent of uterine muscle contraction, measured in grams (g). The analysis is undertaken by attaching myometrial strips between an isometric force transducer and the base of an organ bath chamber.
Time frame: 4 hours
Frequency of contraction
The number of contractions in uterine muscle (myometrium) over 10 minutes, spontaneously and in response to an agonist. The analysis is undertaken by attaching myometrial strips between an isometric force transducer and the base of an organ bath chamber.
Time frame: 4 hours
Integrated area under response curve (AUC)
Time frame: 4 hours
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Jun 2027, 21 months after the start.
Of 112 non-industry interventional studies with no phase under Postpartum Hemorrhage, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 21 months is above that.
Counting every sponsor, half of 119 studies reached it within 16 months; a quarter within 7 and three quarters within 26.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Jun 2026 → Jun 2027 and completion Jun 2026 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oxytocin
Samuel Lunenfeld Research Institute, Mount Sinai Hospital →